Search

Search Constraints

You searched for: Author/Creator Johnson, Philip J

Search Results

1. Applicability of albumin‐bilirubin‐based Japan integrated staging score in hepatitis B‐associated hepatocellular carcinoma. Issue 10 (October 2016)

2. Characterisation of dysplastic liver nodules using low‐pass DNA sequencing and detection of chromosome arm‐level abnormalities in blood‐derived cell‐free DNA. Issue 1 (7th July 2021)

3. Impact of the introduction of direct‐acting anti‐viral drugs on hepatocarcinogenesis: a prospective serial follow‐up MRI study. Issue 2 (10th June 2020)

4. Incorporating albumin–bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma. Issue 1 (January 2017)

5. Integration of albumin–bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. Issue 7 (27th July 2016)

6. Optimisation of pharmacy content in clinical cancer research protocols: Experience of the United Kingdom Chemotherapy and Pharmacy Advisory Service. (June 2015)

7. P21 Lack of NAFLD-related hepatocellular carcinoma surveillance may explain more advanced stage at diagnosis and worse median survival. (20th September 2022)

9. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. (August 2017)